	US 12,226,426 B2
	Combination therapy
Peter Sarkies, London (GB)
Assigned to IMPERIAL COLLEGE INNOVATIONS LIMITED, London (GB)
Appl. No. 17/279,205
Filed by IMPERIAL COLLEGE INNOVATIONS LIMITED, London (GB)
PCT Filed Sep. 25, 2019, PCT No. PCT/GB2019/052703 § 371(c)(1), (2) Date Mar. 24, 2021, PCT Pub. No. WO2020/065309, PCT Pub. Date Apr. 2, 2020.
Claims priority of application No. 1815579 (GB), filed on Sep. 25, 2018.
Prior Publication US 2022/0031722 A1, Feb. 3, 2022
Int. Cl. A61K 31/7036 (2006.01); A61K 31/255 (2006.01)

CPC A61K 31/7036 (2013.01) [A61K 31/255 (2013.01)]

19 Claims

1. A method of suppressing, reducing or removing an infection with a pathogen in a subject, said method comprising administering a therapeutic combination to the subject, wherein said therapeutic combination comprises:

a. an aminoglycoside antibiotic; and

b. a nucleic acid monoalkylating agent that substitutes a single nucleotide of a nucleic acid with an alkyl group;

wherein the therapeutic combination provides an enhanced suppression of a pathogen when compared with an otherwise identical composition lacking said aminoglycoside antibiotic; or

wherein the therapeutic combination provides an enhanced suppression of a pathogen when compared with an otherwise identical composition lacking said nucleic acid monoalkylating agent.